Checkpoint inhibitor use increases healthcare costs in NSCLC
- PDF / 186,308 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 4 Downloads / 208 Views
PharmacoEconomics & Outcomes News 860, p8 - 22 Aug 2020 Checkpoint inhibitor use increases healthcare costs in NSCLC Use of checkpoint inhibitor (CPI) immunotherapy (atezolizumab, nivolumab or pembrolizumab) in patients with non-small cell lung cancer (NSCLC) appears to increase healthcare costs, according to findings of a US study published in Clinical Therapeutics. IBM Watson Health MarketScan Commercial and Medicare Supplemental Claims and Encounters reimbursed administrative claims data from October 2012 to September 2017, before and after US FDA approval of nivolumab, pembrolizumab and atezolizumab, were used to compared healthcare utilisation and expenditure in 3095 patients with NSCLC treated with CPI compared with those in 3095 propensity score-matched patients eligible for CPI who received other treatments. Utilisation of programmed death ligand-1 (PD-L1) immunohistochemistry testing, and tests for EGFR (epidermal growth factor receptor) mutations and ALK (anaplastic lymphoma kinase) rearrangements, decreased in CPI- and nonCPI-treated cohorts after approval of CPIs by the FDA. Medical resource use was higher in CPI-treated patients than in propensity score-matched patients who received other treatments (p
Data Loading...
